HannaH was a phase III, randomized, international, open–label study that compared pharmacokinetics (PK), efficacy, and safety of two different trastuzumab formulations in HER2–positive, operable, locally advanced, or inflammatory breast cancer in the neoadjuvant/adjuvant setting.

The authors now report updated safety and efficacy data after a median follow–up of 20 months. Overall, the safety profile of SC trastuzumab was consistent with the previously published data from HannaH and the known safety profile of IV trastuzumab. EFS rates were comparable between the IV and SC groups.

READ FULL ARTICLE Curated publisher From Mdlinx